Objective:

To document the efficacy of telitacicept in a patient with IgA nephropathy, stage 4 chronic kidney disease, and acute renal failure.

Approach:

• Patient Profile: A 47-year-old male with stage 4 CKD and acute kidney injury diagnosed with IgAN via biopsy.
• Treatment Protocol: Administered 240 mg of telitacicept for 6 months, followed by gradual reduction and maintenance therapy for 12 months.

Key Findings:

• Proteinuria decreased from 2.82 g/day to 0.60 g/day.
• eGFR improved from 26.95 to 35.69 mL/min/1.73 m² over 18 months.
• Serum albumin levels increased steadily.
• Hematuria gradually declined.
• No infections or adverse events were observed.

Interpretation:

Limitations:

• Single case study limits generalizability.
• Lack of control group for comparison.

Conclusion: